RankAlpha logo
Back to Rankings

KLRS

Kalaris TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Supportive repeat-dose TH103 data and a viable Phase 3 regimen could strengthen the development case. The SEC-filed company release reported ongoing dosing and preliminary data expected in the first half of 2027.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Low coverage, loose valuation comparators and no supplied recent-news or verified analyst-revision set limit near-term visibility.
Momentum
74
Value
57
Sentiment
59
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.00 · Bull $3.40 · Bear $0.75Analysis 2026-10-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-28 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-25 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-28

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $18.71
Why
Momentum74 · Δ7d -
Value57 · Δ7d -0.2
Sentiment59 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Value remains the lead driver in the composite, 7D delta -0.2.

Contradictions & invalidation

  • • Low coverage, loose valuation comparators and no supplied recent-news or verified analyst-revision set limit near-term visibility.
  • • TH103 safety, efficacy or dose-selection results may not support Phase 3 development. [#SEC-8K-2026-08-11]
  • • Clinical results, dose selection, manufacturing execution or timing could disappoint, while spending may shorten the stated runway.

Catalyst clock

2027-06-30

TH103 Phase 1b/2 preliminary data

Lead driver: Value · See fundamentals
Momentum
74
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.8
Sentiment
59
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 74.5 / Value 56.5 / Sentiment 59.2

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-25. Scenario method

B+
Bull case
25%
Probability
Target price
$3.40
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-28
Market Cap
$43.9M
Beta
-0.10
Shares Out
23.81M
P/E (TTM) · Derived
-0.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.89
Rev YoY
-100.0%
EPS YoY
-20.3%
Gross Margin
-
Op Margin
-
Net Debt
-$116.53M
Current Ratio
10.92
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data